These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6442472)

  • 1. Gabexate mesilate (Foy) as an anticoagulant in extracorporeal circulation in dogs and sheep.
    Oedekoven B; Bey R; Mottaghy K; Schmid-Schönbein H
    Thromb Haemost; 1984 Dec; 52(3):329-32. PubMed ID: 6442472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracorporeal anticoagulation using a serine protease inhibitor in hemodialysis in sheep.
    Mottaghy K; Oedekoven B; Bey R; Schmid-Schönbein H
    Trans Am Soc Artif Intern Organs; 1985; 31():534-6. PubMed ID: 3939276
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of HPLC measurement of plasma concentration of gabexate mesilate.
    Nishijima MK; Takezawa J; Taenaka N; Shimada Y; Yoshiya I
    Thromb Res; 1983 Jul; 31(2):279-84. PubMed ID: 6415853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
    Akizawa T
    Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits.
    Annich G; White T; Damm D; Zhao Y; Mahdi F; Meinhardt J; Rebello S; Lucchesi B; Bartlett RH; Schmaier AH
    Thromb Haemost; 1999 Nov; 82(5):1474-81. PubMed ID: 10595641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gabexate mesilate (FOY) on ischemia-reperfusion-induced acute lung injury in dogs.
    Luh SP; Tsai CC; Shau WY; Chen JS; Kuo SH; Lin-Shiau SY; Lee YC
    J Surg Res; 1999 Dec; 87(2):152-63. PubMed ID: 10600344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulability and fibrinolytic changes during veno-venous bypass in liver transplantation.
    Ohkohchi N; Sasaki T; Katoh H; Namiki K; Koizumi M; Sakurada M; Taguchi Y; Mori S; Fujimoto H; Endoh E
    Tohoku J Exp Med; 1987 Aug; 152(4):375-80. PubMed ID: 3116722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
    Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
    Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
    Kaizu K; Uriu K; Ikeda M
    Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
    [No Abstract]   [Full Text] [Related]  

  • 11. [The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis].
    Heitz J; Semsch B; Emde C; Jansen U; Schäfer JH
    Z Gastroenterol; 1990 Apr; 28(4):192-7. PubMed ID: 2119091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental results using nafamostat mesilate as anticoagulant during extracorporeal lung assist for 24 hours in dogs.
    Okamoto T; Chung YK; Choi H; Terasaki H; Morioka T
    Artif Organs; 1993 Jan; 17(1):30-6. PubMed ID: 8422232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arvin anticoagulant for prolonged extracorporeal membrane oxygenation (author's transl)].
    White JJ; Bell W; Matthews P; Büky B
    Anaesthesist; 1976 Nov; 25(11):526-8. PubMed ID: 1008240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of unfavourable effects of heparin with use of gabexate mesilate in dialysis.
    Matsui N; Nakagawa S; Sasaoka T; Suenaga M; Yoshiyama N; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1979; 16():135-40. PubMed ID: 121458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gabexate mesilate and heparin responsiveness in coronary patients.
    Ranucci M
    Med Sci Monit; 2004 Mar; 10(3):PI40-3. PubMed ID: 14976449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY).
    Taenaka N; Shimada Y; Hirata T; Nishijima M; Yoshiya I
    Crit Care Med; 1982 Nov; 10(11):773-5. PubMed ID: 6814824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic responses to prolonged extracorporeal circulation (ECC) with microporous membrane devices.
    Bartlett RH; Fong SW; Woldanski C; Hung E; Styler D; MacArthur C
    Trans Am Soc Artif Intern Organs; 1975; 21():250-7. PubMed ID: 1145997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of synthetic protease inhibitor gabexate mesilate on the attenuation of ischemia/reperfusion injury in canine kidney autotransplantation.
    Inoue S; Sugitani A; Yamamoto H; Kitada H; Motoyama K; Okabe Y; Ohta M; Yoshida J; Nishiyama K; Tanaka M
    Surgery; 2005 Feb; 137(2):216-24. PubMed ID: 15674204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model.
    Suzuki M; Mohri M; Yamamoto S
    Thromb Haemost; 1998 Feb; 79(2):417-22. PubMed ID: 9493601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of the synthetic proteinase inhibitor, FOY, on hypercoagulability after surgery for esophageal carcinoma].
    Usuba A; Motoki R; Koizumi Y; Oishi A; Endo Y; Konno O; Inoue H
    Nihon Geka Gakkai Zasshi; 1990 Aug; 91(8):931-41. PubMed ID: 2122227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.